Category

Drug Policy

Drug Policy changes

Kicking 2020 to the curb

By Drug Policy, Events Calender, Uncategorized

 

Happy New Year 2021
Fireworks image (2003) by KF420.ca jn Calgary, Alberta Intenational Global Fest.
Happy New Year 2021

 

The year of the Covid 19 coronavirus pandemic changes were many and the lockdowns in countries around the world. Add
Calgary 420 started 2020 with a 420 winter event with our long time awesome comedian friends gathered by Calgary’s own James Moore of the Comedy Monday Night fame. Add supporers such as Calgary 420 volunteers, Jeffrey Lundstrom owner of Skunk Funk Smoker’s Emporium also see the public Facebook group Saskatoon Cannabis Club and The Calgary Cannabis Club

 

 

2020 = the year of the selfish idiot.

.

 

Insisting on your rights without
acknowledging your responsibilities
isn’t freedom, it’s adolescence.

 

 

The rest of the year followed with events being cancelled, lock downs at home and crowded hospitals with virus outbreaks shutting down visiting of dying loved ones. Work from home became the norm for many except essential workers/heroes in health care, transportation and many others. The oddest thing had to be panic buying of toilet paper.

 

    Condolences to all those that lost loved ones to the Covid 19 virus.

 

2020 will be one for the history books that does not need to be repeated.

Legalized Cannabis 1.50 in 2020 event poster.
Legalized Cannabis 1.50 in 2020 event poster

 

Kick 2020 to the curb!
.

 

#COVID-19 #COVIDIOT #pandemic #vaccines #cannabis #420 #calgary

 


 

Canada Gazette, CANNABIS ACT

By Drug Policy

December 12, 2020

DEPARTMENT OF HEALTH

CANNABIS ACT

Notice of intent — Consultation on the Cannabis Regulations: Cannabis research and other regulatory issues

Introduction

This notice provides interested stakeholders with the opportunity to comment on Health Canada’s intent to amend the Cannabis Regulations (CR) and associated regulatory frameworks to facilitate non-therapeutic cannabis research involving human participants and cannabis testing (Part 1).

This notice also provides interested stakeholders with the opportunity to provide feedback and comment on additional regulatory issues: namely public possession limit amounts (i.e. the amounts of various classes of cannabis that are equivalent to 1 gram of dried cannabis, as set out in Schedule 3 to the Cannabis Act); product labelling; micro class and nursery licences; and COVID-19 measures (Part 2).

PART 1: Proposed regulations amending the Cannabis Regulations and associated regulations to facilitate non-therapeutic cannabis research involving human participants and cannabis testing

Background

The Cannabis Act (the Act) creates a strict legal framework for the production, distribution, sale, import, export and possession of cannabis in Canada. Among the objectives of the Act are enhancing public awareness of the health risks associated with cannabis use and providing access to a quality-controlled supply of cannabis.

To help achieve these objectives, Health Canada established a licensing framework to authorize research and development, and testing activities with cannabis under the CR. This included establishing a dedicated research licence class that authorizes activities with cannabis for the purpose of research, as well as authorizing federal licence holders to conduct research and development activities as part of the activities authorized under their licences. Similarly, the authorized activities of government laboratories referred to in section 4 of the CR and the analytical testing licence class permit cannabis testing activities (e.g. for contaminants, cannabinoid content). Other licence holders may also conduct their own testing activities if authorized under their licence, subject to certain conditions.

Under the Cannabis Exemption (Food and Drugs Act) Regulations (CER), cannabis, as defined in the Act and in relation to an activity conducted in accordance with the Act, is exempt from the application of the Food and Drugs Act (FDA) under specific conditions. Cannabis is not exempt from the FDA where it is sold to be used for the purpose of a clinical trial as defined in the Food and Drug Regulations (FDR) [i.e. investigations involving human participants for certain purposes] or an experimental study as defined in those Regulations. Currently, research activities with cannabis involving human participants that meet the definition of clinical trial must meet the relevant requirements of both the CR and the FDR in order to be authorized.

Health Canada recognizes that conducting research involving human participants with cannabis is critical to generating high-quality evidence to provide adult Canadians with the necessary knowledge to make informed decisions on their consumption of cannabis and its risks. Health Canada is aware that researchers are interested in studying the psychological and physiological effects of commercially available cannabis products from a non-therapeutic perspective. Non-therapeutic studies can include investigating the time to onset or duration of effects of a cannabis product, the impact of cannabis use on driving performance, or various other types of public health research. Health Canada is also aware of academic and industry researchers facing challenges in conducting non-therapeutic research involving human participants with cannabis products that are commercially available due to having to comply with the clinical trial requirements under Division 5 of Part C of the FDR.

Regulatory proposal

Health Canada is considering proposing amendments to the CR and associated regulatory frameworks to facilitate non-therapeutic research with cannabis involving human participants, and to facilitate testing activities with cannabis. The proposed amendments would

  • (1) Facilitate non-therapeutic cannabis research involving human participants by
    • implementing appropriate health and safety controls, and
    • broadening adverse reaction reporting, where necessary; and
  • (2) Streamline and rationalize the licensing framework under the CR to facilitate cannabis-based testing activities, including
    • expanding production, distribution, and sale activities with cannabis reference standards and test kits, and
    • expanding the acceptable qualifications of the “head of laboratory.”

In recognition that Division 5 of Part C may not be ideally suited to regulate non-therapeutic cannabis research involving human participants, Health Canada is considering amendments to the CR, the CER and the FDR to regulate studies of this nature exclusively under the Act and the CR. The regulatory changes would include appropriate public health and public safety controls, as well as controls to ensure the integrity of research findings. Among these controls, the Department is considering proposing amendments to broaden adverse reaction reporting to include licence holders conducting cannabis research involving human participants for non-therapeutic purposes.

Additional related amendments are being considered to the licensing framework under the CR to better support cannabis-based testing activities. Cannabis reference standards play a vital role in assisting laboratories in accurately testing different product characteristics and validating the accuracy of their testing methods, which contribute to maintaining a quality-controlled supply of cannabis products. Reliable testing results help build consumer and industry confidence that the cannabis products available on the retail market are quality controlled and properly labelled (e.g. cannabinoid content is within the labelled amount). Research and analytical testing licence holders, as well as government laboratories referred to in section 4 of the CR, are currently authorized to conduct limited activities with cannabis reference standards (e.g. possess, distribute), but they are not permitted to sell these products. In order for them to do so, they need to obtain a processing licence and comply with good production practices (GPP). GPP requirements are not necessary for reference standards, as they are not intended to be sold to consumers. Therefore, Health Canada is considering exempting licence holders and government laboratories from the GPP requirements when they conduct activities with reference standards. Health Canada also intends to authorize research and analytical testing licence holders, as well as government laboratories, to produce cannabis test kits, and produce and sell cannabis reference standards. The CR already authorizes the sale of test kits.

In addition, Health Canada is considering expanding the acceptable qualifications for a “head of laboratory” (the individual responsible for testing activities). This proposed change intends to help ensure that qualified individuals with sufficient experience and a range of different academic credentials would be eligible to hold this position.

Questions to guide input from interested parties

Below are key questions for which Health Canada is particularly interested in receiving input. However, all input is welcome and should not be limited to responses to these questions. Please provide a rationale and/or evidence to support your views wherever possible.

  • 1. How likely would you conduct non-therapeutic cannabis research involving human participants? How many studies do you envision conducting in a year?
  • 2. Should the requirements to conduct non-therapeutic cannabis research involving human participants under the CR be similar to those that currently apply to clinical trials under the FDR (e.g. protocol review by a research ethics board, submission of extensive quality [chemistry and manufacturing] information, review of written informed consent, and submission of an investigator’s brochure)? If the requirements should differ, how?
  • 3. Should non-therapeutic research involving human participants be restricted to certain participants (e.g. exclude individuals with previous/current mental health or substance use disorders, age restrictions)?
  • 4. Should there be restrictions on the types of cannabis used in non-therapeutic cannabis research involving human participants? If so, under what circumstances? What should the quality requirements be for cannabis derived from synthetic sources?
  • 5. Should there be restrictions on the dosage, frequency, duration and route of administration (e.g. smoking or vaping) of cannabis used in non-therapeutic cannabis research involving human participants?
  • 6. Should adverse reaction reporting for non-therapeutic cannabis research involving human participants be treated in a similar manner as adverse reaction reporting for clinical trials under the FDR? Why or why not?
  • 7. What are your thoughts on expanding the production, distribution and sale activities of cannabis reference standards and test kits? What are the potential risks and benefits of this approach (e.g. by exempting reference standards from GPP requirements)?
  • 8. Are there any impediments stemming from the current requirements for the “head of laboratory” under the CR?

PART 2: Feedback on additional regulatory issues

In addition to seeking input from interested stakeholders on Health Canada’s intent to propose amendments to the CR and associated regulatory frameworks to facilitate non-therapeutic cannabis research involving human participants and cannabis testing, Health Canada is also seeking input on the topics below. There are key questions after each topic for which Health Canada is particularly interested in receiving input. However, all input is welcome and should not be limited to responses to these questions. Please provide a rationale and/or evidence to support your views wherever possible. The responses will help inform potential future regulatory development and will be reviewed carefully by Health Canada.

Public possession limit

Under the Act, individuals 18 years of age and older are prohibited from possessing in public more than 30 grams of dried cannabis or its “equivalent” for non-dried forms of cannabis. Schedule 3 to the Act sets the amounts of various classes of cannabis that are considered equivalent to 1 gram of dried cannabis. These amounts generally align with U.S. jurisdictions that have legalized and regulated cannabis for non-medical purposes.

To help individuals comply with the public possession limit, the CR require that all cannabis products for retail sale, except for dried cannabis or a cannabis plant, be labelled with a statement indicating the amount of dried cannabis the product would be equivalent to (i.e. a public possession statement).

In public opinion research conducted in February 2020 by Health Canada, many participants were generally aware that there is a limit for the amount of cannabis that an adult can possess in public, however, very few were aware of what that limit actually is. The public possession statement on product labels was often misunderstood, and many participants in the public opinion research did not associate it with an indication of the public possession limit. Rather, this information was misinterpreted as either serving as a guide of product strength or as a benchmark enabling cost comparison between different cannabis products.

As well, some stakeholders have suggested that the public possession limits for non-solids containing cannabis (e.g. cannabis beverages) are too low, and that the public possession limits are encouraging consumers to purchase higher potency cannabis beverages.

  • 9. Do you think the public possession statement on cannabis product labels helps adults comply with the public possession limit?
  • 10. Currently, the CR require labels to display a statement to express the amount of cannabis a product is equivalent to in terms of grams of dried cannabis. Do you see any issues with this approach? Are there any benefits or challenges you think an adult may have in interpreting this information on different kinds of cannabis products (e.g. edible cannabis, cannabis topicals, vaping products, etc.)?
  • 11. Do you think the current public possession limit for cannabis beverages (which is currently approximately 2 litres) should be increased? If yes, please explain what you think an appropriate public possession limit would be for these products and why.

Product labelling

Cannabis contains hundreds of chemical substances, including cannabinoids (such as tetrahydrocannabinol [THC] and cannabidiol [CBD]) and terpenes. The CR require that product labels indicate the quantity or concentration of the THC and CBD in cannabis products. Licence holders may choose to display the name, quantity or concentration of other cannabinoids and terpenes in the product, provided that the labelling and packaging comply with the CR.

  • 12. Should Health Canada require product labels to display information about other cannabinoids and terpenes (e.g. quantity or concentration)? Why or why not? If yes, which cannabinoids and terpenes and why?
  • 13. Is there any other labelling information that would help consumers make decisions to support informed and responsible use?

Micro class and nursery licences

The CR sets out a licensing framework intended to enable a diverse, competitive legal industry that is comprised of a range of market participants, including both small and large players.

Three of the licence subclasses — micro-cultivation, micro-processing, and nursery — are intended to enable the participation of small-scale players. The micro-cultivation and micro-processing licences authorize the same activities as a licence for standard cultivation and standard processing respectively, but at a smaller scale. The nursery licence is intended to enable a legal source of starting materials (both for commercial and personal cultivation), and the development of new varieties of high quality cannabis.

These licences are subject to reduced regulatory requirements (e.g. in the area of physical security), which reflects the level of risk related to the scale of the operation.

  • 14. Are the regulatory requirements for the micro-cultivation, micro-processing and nursery licences (e.g. cultivation and processing limits) appropriate given their scale?
  • 15. Are there any elements of the regulatory framework that put micro-cultivation, micro-processing and nursery licence holders at a competitive disadvantage compared to larger companies? If so, how, and what adjustments would you propose?

COVID-19 measures

Since April 2020, Health Canada has put in place measures to support cannabis licence holders with operational and logistical difficulties that they may be facing due to the COVID-19 pandemic. These include, among others, accepting a packaging date that is within four (4) days of the printed packaging date on the label (provided appropriate records are kept), enabling the destruction of cannabis to be witnessed virtually and simplifying the requirements for the presence of a security cleared person accompanying cannabis being treated at an external destruction or irradiation facility. These measures are in place until March 31, 2021.

  • 16. Are there any measures that should be made permanent? What would be the impact if these measures were not continued? Are there any risks of making a measure permanent and how should they be mitigated?

Conclusion

The publication of this notice in the Canada Gazette, Part I, initiates a 30-day comment period. Health Canada is seeking feedback and comments to ensure that the proposed regulatory amendments with respect to cannabis research and testing are informed by and responsive to the cannabis industry, cannabis researchers, other relevant stakeholders and the public. The Department is also interested in views on a variety of other aspects related to the regulatory framework. Any inquiries or comments for this notice must be sent by email to cannabis.consultation@canada.ca stating the title of this notice (Notice of intent —Consultation on the Cannabis Regulations: Cannabis research and other regulatory issues) in the subject line.

John Clare
Director General
Strategic Policy, Cannabis
Controlled Substances and Cannabis Branch

Canada Gazette, Part I, Volume 154, Number 50: GOVERNMENT NOTICES December 12, 2020

 

The UN Votes to Recognise the Potential Medical value of Cannabis

By Drug Policy

December 2, 2020

The UN Votes to Recognise the Potential Medical value of Cannabis

The UN Votes to Recognise the
Potential Medical value of Cannabis

Prohibition Partners (PP)
Intelligence LTD A Prohibition Holdings Company.

The UN has just accepted
recommendations made by the

World Health Organisation
which reschedule cannabis and

cannabis related
substances, effectively accepting the medical potential of cannabis.

#cannabis #marijuana #medicalcannabis
#medicalmarijuana #prohibition #UN

https://prohibitionpartners.com/2020/12/02/the-un-votes-to-recognise-the-potential-medical-value-of-cannabis/

 

2 Years since legalization

By Drug Policy, Government, News Media

 

Canadian government gets ‘C’ average in the legalization report card

October 17, 2020
Sam Riches – The GrowthOp
A new report by the Cannabis Council of Canada reviews the legal industry’s performance over the past two years

[picture] FILE: A worker tends to marijuana plants at the Aurora Sky facility in Edmonton, Alberta, Canada, on Tuesday, March 6, 2018. Jason Franson/Bloomberg

A new report from the Cannabis Council of Canada, which represents some of the country’s largest licensed producers, including Canopy Growth, Tilray, and Cronos Group, has graded the government’s performance over the first two years of legalization with a ‘C’ average.

thegrowthop.com/cannabis-news/canadian-cannabis-industry-gets-c-average-in-the-legalization-report-card

&nbsp

‘It’s changed so much’: Alberta cannabis retailers, growers reflect on success as legal industry turns 2

October 18, 2020
Eloise Therien – Global News

Oct. 17 marked the second anniversary of cannabis legalization in Canada. Eloise Therien caught up with local retailers and growers to find out how the industry has changed within that time

Canada became the second country to legalize the sale and consumption of marijuana on October 17th, 2018 — meaning Saturday marked the two-year anniversary of the industry.

See more @ globalnews.ca/news/7403733/alberta-cannabis-second-anniversary

&nbsp

Illegal cannabis market still thriving in Canada two years after legalization

October 19, 2020
Sonia Aslam – The Canadian Press

[picture] FILE – In this March 21, 2015 file photo, a man rolls a marijuana cigarette as a large group gathered near the New Jersey Statehouse to show their support for legalizing marijuana, in Trenton, N.J. (AP Photo/Mel Evans, File)

It’s been two years since Canada legalized recreational marijuana, but the illegal market is still thriving.

See more @ citynews1130.com/2020/10/19/cannabis-canada-legalization

 


 

#164 Activist Keith Fagin – A Sensible Approach

By Drug Policy, News Media

My interview with #Calgary-based activist & educator Keith Fagin (@kf420) is up! His stories are awesome, his perspective is even better. I hope you enjoy

Anchor FM Inc. https://t.co/ymZbzXrvuT

Old guard cannabis activists rally to support Keith Fagin, one of their own

By Drug Policy, News Media

2010 occupation of Canadian Prime Minister Stephen Harper's Calgary constituency office

December 20, 2019

‘Keith represents the type of person who made cannabis law reform happen in Canada,’ says Jodie Emery

John Conroy met Fagin while they were both working together at the National Organization for the Reform of Marijuana Canadian Chapter in the early ’70s. Conroy went on to serve as NORML Canada‘s president and Fagin became its regional director for the prairies.

“This man deserves support from all of the people he’s helped and for all of the great work he’s done in Alberta⁠ — both him and his wife Debbie,” Conroy said. “I was very sad to see what had happened to him and felt he was very deserving of getting the stuff he needs to get mobile again.”

Dana Larsen

Keith Fagin is a cannabis hero and he needs our help now.

Please donate a few bucks to help out.

Fagin has been involved in the modern cannabis movement since its early days, said Dana Larsen, director of the Vancouver Dispensary Society.

Fagin helped found one of the country’s first compassion clubs, Calgary 420, Larsen said. He was always willing to talk about why Canada needed to legalize cannabis and defend the culture — and then once legalization happened, Fagin was ready to educate people about how flawed the system still is.

https://mugglehead.com/keith-fagin-gofundme/


Driving Simulator: THC dosing associated with decreased speed, no residual effects on performance

By Drug Policy

Driving Simulator THC dosing

Subjects typically decrease their driving speed, but demonstrate few other significant changes following cannabis inhalation, according to clinical data published in the journal Drug and Alcohol Dependence.

https://www.ncbi.nlm.nih.gov/pubmed/31678833/

2002 to 2019 Cannabis & impaired driving studies
https://calgary420.ca/impaired/#driving


NORML Canada Launches Post-Legalization Platform

By Drug Policy, News Media

NORML Canada
October 11, 2019 08:30 ET | Source: NORML Canada – www.norml.cainfo@norml.ca

NORML Canada launches official Post-Legalization platform to focus advocacy efforts on reforming Canada’s legal Cannabis system.

In light of the first year of legalization, NORML Canada has monitored the Canadian cannabis landscape closely, to determine the next steps for crafting achievable and functional reform of cannabis regulations.

The five key “pillars” established by NORML Canada are designed to help focus organizational resources to support our ongoing government and public outreach.

1) Increased Access
Our goal is to ensure consumers have ease of access to legal cannabis products, access to medical dispensaries, access to world-class product options, as well as access to affordable legal options.

2) Transitioning “Unregulated Market” into the legal framework
Creating avenues for the current unlicensed market to be welcomed as part of the legal cannabis industry in order to achieve the government’s stated goal of disincentivizing the illicit market.

3) Social discrimination protections
Putting in place protective regulations that remove stigma barriers and consequences for consumers in the workplace, housing, and family.

4) US relations – border & banking
Ensuring international respect for Canada’s sovereign laws. Removal of any unnecessary international banking/travel barriers for legal business and cannabis entrepreneurs.

​​5) Expungement, apologies, reparations & beyond
Government must acknowledge the fact that cannabis laws were historically unjust and discriminatory in the first place.

NORML Canada invites the public and press to join us at the historic Hotbox Lounge on Oct 17th, from 4-7pm to launch the new official platform, and to discuss the year-to-date.

NORML Canada proudly welcomes our sister chapter to the South – NORML Michigan, to share insights on Michigan’s newly passed legal recreational cannabis bill. Our combined goals are to understand how we can learn from and collaborate with one another.

About NORML Canada

NORML Canada is a non-profit, public interest, member operated and funded group, chartered at the federal level in Canada since 1978. US NORML advocates for consumers rights to access high quality, safe, convenient & affordable cannabis. NORML was founded in California, 1970.

Media inquiries Contact:
Abi Roach
Alex Krause
www.norml.cainfo@norml.ca

Lottery: Summary of lottery entries received by region August 20, 2019

By Drug Policy

Allocation Lottery: Topline Results

Alcohol and Gaming Commission of Ontario
As set out in Ontario Regulation 468/18, the Government of Ontario gave the AGCO the mandate to hold an Allocation Lottery to determine who may apply for a Retail Operator Licence. The Lottery selection was completed on August 20, 2019 at 12:19pm EDT.

www.agco.ca/cannabis/summary-lottery-entries-received-region